Development
Gilead Sciences, Inc.
GILD
$112.46
-$2.05-1.79%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -0.61% | 0.94% | -0.48% | -1.56% | -0.09% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.61% | 0.94% | -0.48% | -1.56% | -0.09% |
| Cost of Revenue | 5.59% | 2.94% | -0.12% | 0.81% | 2.37% |
| Gross Profit | -2.23% | 0.41% | -0.58% | -2.17% | -0.71% |
| SG&A Expenses | 7.37% | 22.63% | 21.23% | 12.04% | 8.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.13% | 15.87% | 12.27% | 7.69% | 5.90% |
| Operating Income | -15.03% | -19.53% | -17.30% | -13.68% | -7.81% |
| Income Before Tax | 17.99% | 59.34% | 32.50% | 23.95% | -29.77% |
| Income Tax Expenses | 0.00% | 14.27% | 32.66% | 26.04% | -39.91% |
| Earnings from Continuing Operations | 22.91% | 76.13% | 32.44% | 23.31% | -26.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 100.00% | 88.00% | 50.00% | 87.50% | 8.33% |
| Net Income | 23.34% | 76.21% | 32.56% | 23.65% | -26.23% |
| EBIT | -15.03% | -19.53% | -17.30% | -13.68% | -7.81% |
| EBITDA | -8.12% | -13.37% | -12.79% | -10.80% | -6.28% |
| EPS Basic | 23.94% | 77.09% | 33.02% | 23.92% | -26.14% |
| Normalized Basic EPS | -12.61% | -17.42% | -15.55% | -12.09% | -6.83% |
| EPS Diluted | 23.16% | 76.17% | 32.81% | 23.91% | -26.07% |
| Normalized Diluted EPS | -12.79% | -17.74% | -15.81% | -12.26% | -6.93% |
| Average Basic Shares Outstanding | -0.50% | -0.50% | -0.38% | -0.22% | -0.10% |
| Average Diluted Shares Outstanding | -0.30% | -0.10% | -0.04% | 0.00% | 0.02% |
| Dividend Per Share | 2.74% | 2.76% | 2.78% | 2.80% | 2.82% |
| Payout Ratio | -0.17% | -0.42% | -0.23% | -0.17% | 0.39% |